Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails
NE Munk, JS Knudsen… - Sexual medicine …, 2019 - academic.oup.com
Introduction On-demand phosphodiesterase type 5 inhibitor (PDE5i) monotherapy is a first-
line treatment for erectile dysfunction (ED), but 30%–40% of patients exhibit little or no …
line treatment for erectile dysfunction (ED), but 30%–40% of patients exhibit little or no …
Combination therapy with alpha-blocker and phosphodiesterase-5 inhibitor for improving lower urinary tract symptoms and erectile dysfunction in comparison with …
P Kallidonis, C Adamou, D Kotsiris, P Ntasiotis… - European urology …, 2020 - Elsevier
Context The effects of combination therapy consisted of an α-blocker and a
phosphodiesterase-5 inhibitor (PDE5I) for the treatment of lower urinary tract symptoms …
phosphodiesterase-5 inhibitor (PDE5I) for the treatment of lower urinary tract symptoms …
Placebo responses among men with erectile dysfunction enrolled in phosphodiesterase 5 inhibitor trials: a systematic review and meta-analysis
A Stridh, M Pontén, S Arver, I Kirsch, C Abé… - JAMA network …, 2020 - jamanetwork.com
Importance Placebo responses in the treatment of erectile dysfunction (ED) are poorly
described in the literature to date. Objective To quantify the association of placebo with ED …
described in the literature to date. Objective To quantify the association of placebo with ED …
Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic …
J Zhang, X Li, B Yang, C Wu, Y Fan, H Li - World journal of urology, 2019 - Springer
Purpose Recently, several randomized controlled trials (RCTs) explored the effects of α-
blockers with or without phosphodiesterase type 5 inhibitors (PDE5-Is) for lower urinary tract …
blockers with or without phosphodiesterase type 5 inhibitors (PDE5-Is) for lower urinary tract …
Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate
S Ückert, GT Kedia, D Tsikas, A Simon… - World journal of …, 2020 - Springer
Objectives The benign prostatic syndrome, comprising lower urinary tract symptomatology
secondary to benign prostatic hyperplasia/enlargement, represents a major health care …
secondary to benign prostatic hyperplasia/enlargement, represents a major health care …
Advances in Outpatient Therapies and Treatment of Benign Prostatic Hyperplasia: A Comprehensive Review for Men's Health
TA Helman, BM Browne - Medical Clinics, 2024 - medical.theclinics.com
Benign prostatic hyperplasia (BPH) is a condition that affects a majority of men at some point
throughout their life. Prostate growth causes bladder outlet obstruction and leads to …
throughout their life. Prostate growth causes bladder outlet obstruction and leads to …
[PDF][PDF] Sildenafil vs. tadalafil for the treatment of benign prostatic hyperplasia: a single-arm self-controlled clinical trial
INTRODUCTION PATIENTS AND METHODS Page 1 UNCLASSIFIED Urology Journal/Vol
20 No. 4/ July-August 2023/ pp. 255-260. [DOI:10.22037/uj.v20i.7593] Sildenafil Vs …
20 No. 4/ July-August 2023/ pp. 255-260. [DOI:10.22037/uj.v20i.7593] Sildenafil Vs …
Medical Advancements in Benign Prostatic Hyperplasia Treatments
V Ganesan, D Agarwal - Current Urology Reports, 2024 - Springer
Abstract Purpose of Review This review aims to identify and summarize the current literature
on the most recent therapeutic agents and combination strategies for the medical …
on the most recent therapeutic agents and combination strategies for the medical …
Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms …
L Qiangzhao, Z Xiaofeng, Z Fenghai, L Qiong, Z Fa… - Medicine, 2020 - journals.lww.com
Purpose: This study aimed to compare the efficacy and safety of combination therapy
consisting of α-blockers and different phosphodiesterase type 5 inhibitors for lower urinary …
consisting of α-blockers and different phosphodiesterase type 5 inhibitors for lower urinary …
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign …
C Ma, J Zhang, Z Cai, J Xiong… - BioMed Research …, 2020 - Wiley Online Library
Purpose. The purpose of this study was to compare the relative safety and efficacy of
different types of phosphodiesterase type 5 inhibitors (PDE5‐Is) with tamsulosin for the …
different types of phosphodiesterase type 5 inhibitors (PDE5‐Is) with tamsulosin for the …